ARTICLE | Clinical News
FDA accepts resubmitted NDA for Ironshore's HLD200 for ADHD
July 13, 2018 7:57 PM UTC
The Ironshore Pharmaceuticals & Development Inc. subsidiary of Highland Therapeutics Inc. (Toronto, Ontario) said FDA accepted a resubmitted NDA for HLD200 to treat ADHD. The PDUFA date is Aug. 8...
BCIQ Company Profiles